GlaxoSmithKline Pharmaceuticals Limited

rs,

G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sirs, Subject: Presentation of Analyst / Institutional Investor Meetings Pursuant to Regulation 30 read

0.5%

access and sharp focus Strengthening market leadership Maximize potential in the SITT Market +0.5% Val growth 103 Unit EI 1.2x Vol growth 120 Unit EI 1.1x Vol growth 101 Unit EI ~1.8x Vol

1.2x

gthening market leadership Maximize potential in the SITT Market +0.5% Val growth 103 Unit EI 1.2x Vol growth 120 Unit EI 1.1x Vol growth 101 Unit EI ~1.8x Vol growth 137 Unit EI No 1 br

1.1x

imize potential in the SITT Market +0.5% Val growth 103 Unit EI 1.2x Vol growth 120 Unit EI 1.1x Vol growth 101 Unit EI ~1.8x Vol growth 137 Unit EI No 1 brand in IPM (12/12 months*) 5

1.8x

et +0.5% Val growth 103 Unit EI 1.2x Vol growth 120 Unit EI 1.1x Vol growth 101 Unit EI ~1.8x Vol growth 137 Unit EI No 1 brand in IPM (12/12 months*) 5% Vol MS gain in cefuroxime mark

5%

x Vol growth 101 Unit EI ~1.8x Vol growth 137 Unit EI No 1 brand in IPM (12/12 months*) 5% Vol MS gain in cefuroxime market 76% Vol MS (+0.7% gain) in Mupirocin market ~5.9% Val MS in S

76%

l growth 137 Unit EI No 1 brand in IPM (12/12 months*) 5% Vol MS gain in cefuroxime market 76% Vol MS (+0.7% gain) in Mupirocin market ~5.9% Val MS in SITT class Source: IQVIA Q4 (Jan-Mar’25

0.7%

7 Unit EI No 1 brand in IPM (12/12 months*) 5% Vol MS gain in cefuroxime market 76% Vol MS (+0.7% gain) in Mupirocin market ~5.9% Val MS in SITT class Source: IQVIA Q4 (Jan-Mar’25) ;* AWACS ; C

5.9%

/12 months*) 5% Vol MS gain in cefuroxime market 76% Vol MS (+0.7% gain) in Mupirocin market ~5.9% Val MS in SITT class Source: IQVIA Q4 (Jan-Mar’25) ;* AWACS ; Ceftum counting units used 13 May

21.2%

um counting units used to calculate Unit EI 13 May 2025 4 GSK leading the Vaccines market with ~21.2% market share Year 1 In clinic Promotion and HCP engagement Year 2 Expanding the market throug

9.4%

Rank #1 /#2 Maintain Leadership Ahead of market Havrix & Varilrix EI>100 Driving growth Boostrix 9.4% & Fluarix Tetra 10.4% Source: IQVIA Mar’25 dataset (MQT) 13 May 2025 5 Building equity in resp

10.4%

Leadership Ahead of market Havrix & Varilrix EI>100 Driving growth Boostrix 9.4% & Fluarix Tetra 10.4% Source: IQVIA Mar’25 dataset (MQT) 13 May 2025 5 Building equity in respiratory segment by red

“Cr) 38.8% 34.7% 21.7% 48,743 32,917 28,171 22,432 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Gross Margin as a % of sales EBITDA as a % of revenue from operation ROCE = Profit before Tax (Excl.”

Key highlights

1

Key highlights

1. Aligned operational plans to the integrated patient journey in Q4 FY24-25 – with razor sharp focus on areas of resourcing 2. Overall awareness steady ~18%, shifted focus towards driving more patient activations at point of vaccination 3. Crossed the 10K sell-in barrier for the 1st time in March 2025 since launch month Source: Internal data; Vx : Vaccine, HCP : Health care professionals; PE : Patient Empowerment 7 Accolades & recognitions Great Place to work - Certification Annual OPPI Awards 2024-25 EHS excellence Award 2024-25 received by Nashik manufacturing unit  GSK Worli received, Leesman+ certification  #1 amongst all GSK offices  #2 amongst Leesman measured workplaces globally Winner – Sales Force Excellence Award Adult immunization clinic set up at Fortis Escorts, Heart institute, Delhi – inaugurated by Pankaj Kumar Singh, Minister – Health & Family Welfare, Delhi  Brand – Ceftum  Category - Existing Pharma Product  Winner - Dr. H. R. Nanji Memorial OPPI Marketing Exce